CEBINA publishes data demonstrating the anti-histamine azelastine inhibits infection by major variants of SARS-CoV-2

06 Jul'22

CEBINA announced the publication of research results demonstrating that the commonly used anti-histamine, azelastine, is a potent inhibitor of major variants of SARS- CoV-2 in the peer-reviewed journal Frontiers in Pharmacology (1).

Despite many countries relaxing COVID precautionary measures, experts have warned of a resurgence of SARS-CoV-2 infections already beginning this summer and a return to pandemic restrictions. Since emerging SARS-CoV-2 variants exhibit increased infectivity and existing vaccines have reduced efficacy against emerging mutants it is vitally important to limit the spread of SARS-CoV-2 with additional anti-COVID approaches. The data presented in the newly published research paper describes the application of a novel computational prediction approach for the identification of the anti-histamine drug, azelastine as anti-COVID-19 approach. The data demonstrate the comparable potency and efficacy of Azelastine against the original, alpha, and delta variants SARS-CoV-2 virus in cell culture and reconstituted human nasal tissue.

Back